Company: IOBT
Filing Date: 2025-08-11
Form Type: 8-K
Source: 0001193125-25-177471
Chunk: 1

Company: IO Biotech, Inc.
Filing Date: 2025-08-11
Form: 8-K
Item: Item 7.01
Chunk 1
---
Item 7.01.      Regulation FD Disclosure.  

On August 11, 2025, the Company issued a press release announcing topline results from IOB-013, the Company’s Phase 3 trial of Cylembio® in combination with pembrolizumab as a first-line treatment for patients with unresectable or metastatic (advanced) melanoma. The Company is hosting a conference call and webcast at 8:30 am Eastern Time, on August 11, 2025, during which the Company will discuss the topline results and will make a slide presentation.

The press release is attached as Exhibit 99.1 and the form of slide presentation is attached as Exhibit 99.2, and each is incorporated into this Item 8.01 by reference.

The information contained in this Current Report on Form8-Kis being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.